LUZHU BIOTECH-B (02480) announced that a randomized, active-controlled, non-inferiority trial comparing its core product LZ901 with the recombinant glycoprotein E (gE) subunit vaccine HZ/su (Shingrix®) has yielded positive immunogenicity and safety data in adults aged 50 and above.

The study enrolled 301 healthy adults aged 50 or older, with at least 291 healthy adults receiving two doses of either LZ901 or HZ/su vaccine. The research results demonstrated that compared to the HZ/su vaccine, LZ901 induced superior cellular immunogenicity and exhibited better safety profile in adults aged 50 and above.

LZ901 is a recombinant shingles vaccine independently developed by the Group and represents the company's core product, designed to prevent shingles and related complications (including postherpetic neuralgia) in adults aged 40 and above.

As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review.